Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective of this study is to assess the safety and electrical performance of Left ventricular (LV) NAVIGO 4LV leads, pre-shaped (S-shaped&U-shaped: NAVIGO 4LV 2D, NAVIGO 4LV ARC) and Straight (NAVIGO 4LV PILOT), with IS4 connector
The devices under investigation, NAVIGO 4LV models Pilot, 2D , and ARC are the new quadripolar coronary venous leads with polyurethane lead body, intended to be used with defibrillators with ventricular resynchronization therapy.
The new lead design with the presence of 4 electrodes that allows several combinations in programming pacing vectors, is intended to benefit both the patients by improving response to therapy, overcoming high pacing threshold and avoiding phrenic nerve stimulation, and the investigators by reducing the number of re-interventions needed.
This clinical investigation is a pre-market release study intended to analyze safety and electrical performance of NAVIGO 4LV leads pre-shaped (S-shaped & U-shaped) and Straight leads models. The primary endpoint data will be used to support the achievement of the CE mark of NAVIGO 4LV leads.
The primary endpoints will be evaluated at 1 month post-implantation; secondary endpoints will be evaluated up to 2 years post-implantation. The duration of patient inclusion will be approximately 10 months for pre-shaped NAVIGO family (S-shaped &U-shaped) and approximately 21 months for straight ones.
The post implant follows-up visits will take place at Hospital discharge, weeks 10, 6 months and every 6 months until 2 years.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| NAVIGO 4LV implant | Experimental | All patients will be attempted to implant or implanted with NAVIGO 4LV lead |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| NAVIGO 4LV lead implant | Device | All patients will be attempted to implant or implanted with NAVIGO 4LV lead |
|
| Measure | Description | Time Frame |
|---|---|---|
| LV lead Safety at 10 weeks | Freedom from LV lead-related complications, defined as any investigational device deficiency or any serious adverse device event (SADE) that resulted in patient death or required a re-intervention (not including re-programming) that occurred within 30 days after successful implant of the CRT-D system | 10 weeks after implant |
| LV lead Performance at 10 weeks | Successful performance defined as LV pacing threshold at 10 weeks < 2.5 V/0.5 ms observed on at least one pacing vector and absence of phrenic nerve stimulation at programmed pacing amplitude | 10 weeks after implant |
| Measure | Description | Time Frame |
|---|---|---|
| Electrical performance | LV pacing threshold amplitude (V) and LV pacing impedance (Ohm) | through study completion, an average of 6 month |
| Rate of patients free from LV lead-related complications |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Juan Gabriel Martinez Martinez | Hospital General Universitario Alicante Spain | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHRU Brest | Brest | 29609 | France | |||
| CHRU Hopital Trousseau |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38316493 | Derived | Martinez JG, De Sousa J, Dompnier A, Martins-Oliveira M, Israel CW, Teijeira E, Rubin JM, Sebag F, Martino M, Michel Y, Marques P. Efficacy and safety of novel left ventricular pacing leads: 1-year analysis of the NAVIGATOR trial. Open Heart. 2024 Feb 5;11(1):e002517. doi: 10.1136/openhrt-2023-002517. |
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | Jan 26, 2024 | |
| Unrelease | Jan 31, 2024 |
Not provided
NAVIGO 4LV LV leads are available as "S shaped"(NAVIGO 4LV 2D) , "U shaped" (NAVIGO 4LV ARC) and "straight"( NAVIGO 4LV Pilot) models. All the models are available in 78 cm and 88 cm long versions. All models are designed for multipolar pacing (4 electrodes) and all of them have a quadripolar IS4 connector (IS4_LLLL).
The NAVIGO 4LV leads are steroid eluting to avoid adverse effects due to inflammation reaction of the myocardium after positioning of the lead, and therefore to limit the acute pacing threshold peak. The steroid collar design is the same as the one used in all other LIVANOVA leads
Not provided
Not provided
Not provided
Not provided
Freedom from LV lead-related complications defined as any investigational device deficiency or any serious adverse device event (SADE) that resulted in patient death or required a re-intervention (not including re-programming)
| through study completion, an average of 6 month |
| LV lead-related SAEs | Serious Adverse Event LV related | through study completion, an average of 6 month |
| Lead handing assessment of NAVIGO 4LV leads through a questionnaire | A questionnaire on lead handling will track opinion from the investigator, comparing his assessment with this lead to device he is accustomed to implant | Implant |
| NAVIGO 4LV lead implant success rate on enrolled population | To report the NAVIGO 4LV lead implant success rate | Enrollment |
| Number of patients with at least 2 pacing vectors with pacing threshold < 2.5 V at 0.5 ms and no phrenic nerve stimulation | To report the number of patients with at least 2 pacing vectors with pacing threshold < 2.5 V at 0.5 ms and no phrenic nerve stimulation | 10 weeks |
| Number of patients with MP pacing activated | To report the number of patients with MP pacing activated | through study completion, an average of 6 month |
| Rationale to activate MP | To report the reason why physician decide to activate MP to the patient | through study completion, an average of 6 month |
| Number of patients with of at least one MP configuration with no phrenic nerve stimulation at programmed pacing amplitude | To report the number of patients with at least one MP configuration with no phrenic nerve stimulation at programmed pacing amplitude | through study completion, an average of 6 month |
| Number of patients at each final programmed pacing vector and changes | To report number of patients at each final programmed pacing vector and changes | through study completion, an average of 6 month |
| Chambray-lès-Tours |
| 37170 |
| France |
| CH Robert Boulin | Libourne | 33505 | France |
| CHU Hôpital Nord - Marseille | Marseille | 13020 | France |
| Institut Hospitalier Jacques Cartier | Massy | 91349 | France |
| CH Annecy Genevois | Metz-Tessy | 74374 | France |
| Groupe Hospitalier Paris St Joseph | Paris | 75014 | France |
| Institut Mutualiste Montsouris | Paris | 75014 | France |
| CHU Bordeaux | Pessac | 33600 | France |
| CHU Hopital Charles Nicolle | Rouen | 76031 | France |
| CHU Rangueil | Toulouse | 31059 | France |
| Centre Hospitalier de Valence | Valence | 26953 | France |
| CHRU Brabois | Vandœuvre-lès-Nancy | 54500 | France |
| Herz- und Gefässzentrum Bad Bevensen | Bad Bevensen | 29594 | Germany |
| Herz- und Diabeteszentrum | Bad Oeynhausen | 32545 | Germany |
| Deutsches Herzzentrum Berlin | Berlin | 13353 | Germany |
| Evangelisches Krankenhaus | Bielefeld | 33617 | Germany |
| Klinikum Coburg | Coburg | 96450 | Germany |
| Kardiologie Darmstadt | Darmstadt | 64287 | Germany |
| Universitäts-Herzzentrum Freiburg | Freiburg im Breisgau | 79106 | Germany |
| Albertinen-Krankenhau | Hamburg | 22457 | Germany |
| Universitätsklinikum Schleswig-Holstein, Campus Kiel | Kiel | 24105 | Germany |
| Universitatsklinikum | Würzburg | 97080 | Germany |
| Az. Osp-Univ. Ospedali Riuniti Umberto I-Lancisi-Salesi | Ancona | 60126 | Italy |
| Ospedale Universitario Di Pisa | Pisa | 56126 | Italy |
| Az. Osp. Univ. S. Maria della Misericordia | Udine | 33100 | Italy |
| ISALA Klinieken | Zwolle | 10500 | Netherlands |
| Centro Hospitalar Lisboa Ocidental -Hospital de Santa Cruz (CHLO) | Carnaxide | 2799 | Portugal |
| Centro Hospitalar Universitário de Coimbra -Hospitais da Universidade de Coimbra | Coimbra | 3000-075 | Portugal |
| Centro Hospitalar e Universitário de Coimbra - Hospital Geral | Coimbra | 3041-801 | Portugal |
| CHCL - Hospital Santa Marta | Lisbon | 1169-024 | Portugal |
| Centro H. Lisboa Norte - Hospital de Santa Maria | Lisbon | 1649-035 | Portugal |
| Centro Hospitalar do Porto CHP Hospital de Santo Antonio | Porto | 4099-001 | Portugal |
| Hospital General Universitario de Alicante | Alicante | 03010 | Spain |
| Hospital Universitario Gregorio Marañón | Madrid | 28007 | Spain |
| H. Universitario Central de Asturias | Oviedo | 33011 | Spain |
| Hospital Universitario La Fe | Valencia | 46009 | Spain |
| Complejo Hospitalario Universitario de Vigo - Hospital Alvaro Cunqueiro | Vigo | 36312 | Spain |
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Jan 26, 2024 | Jan 31, 2024 |
| ID | Term |
|---|---|
| D001145 | Arrhythmias, Cardiac |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided